Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Antiviral Res ; 143: 246-251, 2017 07.
Artículo en Inglés | MEDLINE | ID: mdl-28461071

RESUMEN

Alphaviruses require conserved cysteine residues for proper folding and assembly of the E1 and E2 envelope glycoproteins, and likely depend on host protein disulfide isomerase-family enzymes (PDI) to aid in facilitating disulfide bond formation and isomerization in these proteins. Here, we show that in human HEK293 cells, commercially available inhibitors of PDI or modulators thereof (thioredoxin reductase, TRX-R; endoplasmic reticulum oxidoreductin-1, ERO-1) inhibit the replication of CHIKV chikungunya virus (CHIKV) in vitro in a dose-dependent manner. Further, the TRX-R inhibitor auranofin inhibited Venezuelan equine encephalitis virus and the flavivirus Zika virus replication in vitro, while PDI inhibitor 16F16 reduced replication but demonstrated notable toxicity. 16F16 significantly altered the viral genome: plaque-forming unit (PFU) ratio of CHIKV in vitro without affecting relative intracellular viral RNA quantities and inhibited CHIKV E1-induced cell-cell fusion, suggesting that PDI inhibitors alter progeny virion infectivity through altered envelope function. Auranofin also increased the extracellular genome:PFU ratio but decreased the amount of intracellular CHIKV RNA, suggesting an alternative mechanism of action. Finally, auranofin reduced footpad swelling and viremia in the C57BL/6 murine model of CHIKV infection. Our results suggest that targeting oxidative folding pathways represents a potential new anti-alphavirus therapeutic strategy.


Asunto(s)
Antivirales/farmacología , Fiebre Chikungunya/virología , Virus Chikungunya/efectos de los fármacos , Virus Chikungunya/fisiología , Interacciones Huésped-Patógeno/fisiología , Infecciones por Alphavirus/virología , Animales , Auranofina/antagonistas & inhibidores , Fiebre Chikungunya/mortalidad , Virus Chikungunya/patogenicidad , Modelos Animales de Enfermedad , Virus de la Encefalitis Equina Venezolana/efectos de los fármacos , Flavivirus/efectos de los fármacos , Células HEK293 , Humanos , Glicoproteínas de Membrana , Ratones , Ratones Endogámicos C57BL , Proteína Disulfuro Isomerasas/farmacología , Pliegue de Proteína , Reductasa de Tiorredoxina-Disulfuro/farmacología , Proteínas del Envoltorio Viral/metabolismo , Replicación Viral/efectos de los fármacos , Virus Zika/efectos de los fármacos , Infección por el Virus Zika/virología
2.
Br J Pharmacol ; 142(4): 749-55, 2004 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15159275

RESUMEN

1. Acute promyelocytic leukaemia (APL) is characterized by a block in differentiation at the promyelocyte stage. Here, we describe the effects of auranofin (AF), a coordinated gold compound, on apoptosis and differentiation of APL cells. 2. Nucleosomal DNA fragmentation assay and Hoechst 33342 staining indicated that AF induced apoptosis in APL-derived NB4 cells at low concentrations (0.5-1.0 microm). The AF-induced apoptosis involved caspase-3 activation and specific cleavage of poly-ADP-ribose polymerase. 3. The AF-treated NB4 cells also produced reactive oxygen species (ROS) and cotreatment with N-acetyl-l-cysteine protected the NB4 cells from AF-induced apoptosis. 4. Expression of the CD11b cell surface marker and C/EBPepsilon was increased when the cells were treated for 4 days with 0.3 microm AF and a physiological concentration of all-trans retinoic acid (ATRA, 5 nm). Treatment with AF in combination with ATRA markedly increased the number of cells with differentiated features, such as lobed or multiple nuclei and numerous granules and vacuoles. At these low concentrations, neither AF nor ATRA alone induced significant cell differentiation. 5. These findings suggest not only that AF induces caspase-3-dependent apoptosis via a mechanism involving ROS, but also that the combined treatment with AF and ATRA induces differentiation of NB4 cells. Our results demonstrate a novel characteristic of AF from which an effective drug treatment of APL might be developed.


Asunto(s)
Apoptosis/efectos de los fármacos , Auranofina/efectos adversos , Quimioterapia Combinada , Leucemia Promielocítica Aguda/tratamiento farmacológico , Tretinoina/uso terapéutico , Acetilcisteína/farmacología , Antígenos de Superficie/efectos de los fármacos , Antígenos de Superficie/genética , Antirreumáticos/efectos adversos , Antirreumáticos/antagonistas & inhibidores , Antirreumáticos/química , Apoptosis/fisiología , Auranofina/antagonistas & inhibidores , Auranofina/química , Bencimidazoles , Antígeno CD11b/genética , Antígeno CD11b/metabolismo , Caspasa 3 , Caspasas/metabolismo , Diferenciación Celular/efectos de los fármacos , ADN/química , ADN/efectos de los fármacos , Colorantes Fluorescentes , Células HL-60 , Humanos , Corea (Geográfico) , Leucemia Promielocítica Aguda/patología , Leucemia Promielocítica Aguda/fisiopatología , Nucleosomas/química , Nucleosomas/efectos de los fármacos , Especies Reactivas de Oxígeno/metabolismo , Transducción de Señal/fisiología , Tretinoina/farmacología , Células Tumorales Cultivadas
3.
Mol Pharmacol ; 31(1): 21-6, 1987 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-3807890

RESUMEN

Metallothioneins (MTs) are low molecular weight, thiol-rich, metal-binding proteins. Auranofin (AF) is a gold compound active in the treatment of rheumatoid arthritis. The effects of AF on regulation of MT gene expression in Chinese hamster ovary cells were studied. AF-resistant cells accumulated substantial amounts of MT mRNA and protein, whereas no induction was observed in AF-sensitive cells. Cells capable of inducing MT in the presence of AF were much less sensitive to AF-mediated cytotoxicity. Induction of MT by low concentrations of Cd protected cells from subsequently administered doses of AF. The level of protection correlated with the level of induced MT. These findings indicate that MT plays a central role in the mechanisms underlying cellular resistance to gold compounds.


Asunto(s)
Auranofina/farmacología , Metalotioneína/biosíntesis , Animales , Auranofina/antagonistas & inhibidores , Auranofina/toxicidad , Cadmio/farmacología , Cadmio/toxicidad , Supervivencia Celular/efectos de los fármacos , Cricetinae , Resistencia a Medicamentos , Regulación de la Expresión Génica/efectos de los fármacos , Metalotioneína/genética , ARN Mensajero/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...